$1.02 Billion is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 97 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 51.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AZN | Sell | ASTRAZENECA PLCsponsored adr | $44,936,000 | -4.5% | 820,000 | -7.9% | 4.42% | -0.3% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $17,559,000 | -28.5% | 1,243,550 | -23.6% | 1.72% | -25.3% |
| NICE | Sell | NICE LTDsponsored adr | $14,185,000 | -42.1% | 62,481 | -51.7% | 1.39% | -39.5% |
| AMZN | Sell | AMAZON COM INC | $12,028,000 | +0.9% | 3,820 | -11.6% | 1.18% | +5.4% |
| MYOK | Sell | MYOKARDIA INC | $11,043,000 | +14.3% | 81,000 | -19.0% | 1.08% | +19.4% |
| KURA | Sell | KURA ONCOLOGY INC | $11,015,000 | +26.4% | 359,494 | -32.7% | 1.08% | +32.1% |
| MSFT | Sell | MICROSOFT CORP | $10,785,000 | -35.3% | 51,278 | -37.4% | 1.06% | -32.4% |
| KRNT | Sell | KORNIT DIGITAL LTD | $9,301,000 | -1.3% | 143,381 | -18.8% | 0.91% | +3.2% |
| Sell | TRILLIUM THERAPEUTICS INC | $9,172,000 | -3.8% | 645,435 | -45.2% | 0.90% | +0.4% | |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $8,329,000 | -12.8% | 253,000 | -27.3% | 0.82% | -8.9% |
| FVRR | Sell | FIVERR INTL LTD | $7,964,000 | -35.4% | 57,301 | -65.7% | 0.78% | -32.4% |
| FATE | Sell | FATE THERAPEUTICS INC | $7,514,000 | -2.7% | 188,000 | -16.4% | 0.74% | +1.7% |
| FISV | Sell | FISERV INC | $7,239,000 | -22.1% | 70,246 | -26.2% | 0.71% | -18.6% |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $5,761,000 | -55.0% | 59,139 | -27.9% | 0.57% | -53.0% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $5,480,000 | -33.3% | 33,000 | -54.2% | 0.54% | -30.4% |
| AXGT | Sell | AXOVANT SCIENCES LTD | $5,327,000 | -33.9% | 1,152,998 | -59.7% | 0.52% | -31.0% |
| RCKT | Sell | ROCKET PHARMACEUTICALS INC | $5,212,000 | -26.8% | 228,016 | -32.9% | 0.51% | -23.5% |
| LRMR | Sell | LARIMAR THERAPEUTICS INC | $5,189,000 | +1.8% | 342,064 | -13.8% | 0.51% | +6.2% |
| ASND | Sell | ASCENDIS PHARMA A/Ssponsored adr | $5,031,000 | -1.0% | 32,599 | -5.2% | 0.49% | +3.3% |
| ZYME | Sell | ZYMEWORKS INC | $3,726,000 | -11.2% | 80,000 | -31.2% | 0.37% | -7.3% |
| PASG | Sell | PASSAGE BIO INC | $3,488,000 | -62.9% | 266,037 | -22.8% | 0.34% | -61.2% |
| CNCE | Sell | CONCERT PHARMACEUTICALS INC | $3,044,000 | -56.3% | 310,000 | -55.8% | 0.30% | -54.4% |
| ADMA | Sell | ADMA BIOLOGICS INC | $2,584,000 | -55.6% | 1,081,292 | -45.5% | 0.25% | -53.6% |
| ORGS | Sell | ORGENESIS INC | $2,010,000 | -50.3% | 398,803 | -40.1% | 0.20% | -48.0% |
| LPTX | Sell | LEAP THERAPEUTICS INC | $1,584,000 | -13.9% | 800,000 | -9.1% | 0.16% | -9.8% |
| XCUR | Sell | EXICURE INC | $1,291,000 | -72.2% | 737,557 | -61.2% | 0.13% | -70.9% |
| SEDG | Sell | SOLAREDGE TECHNOLOGIES INC | $957,000 | -85.0% | 4,017 | -91.3% | 0.09% | -84.4% |
| CRBP | Sell | CORBUS PHARMACEUTICALS HLDGScall | $141,000 | -93.0% | 78,500 | -67.1% | 0.01% | -92.6% |
| TCRR | Exit | TCR2 THERAPEUTICS INC | $0 | – | -30,000 | -100.0% | -0.04% | – |
| CAMT | Exit | CAMTEK LTDord | $0 | – | -37,184 | -100.0% | -0.04% | – |
| NEOS | Exit | NEOS THERAPEUTICS INC | $0 | – | -950,311 | -100.0% | -0.06% | – |
| BLU | Exit | BELLUS HEALTH INC NEW | $0 | – | -97,805 | -100.0% | -0.10% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -200,000 | -100.0% | -0.10% | – |
| IMUX | Exit | IMMUNIC INC | $0 | – | -100,000 | -100.0% | -0.11% | – |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INCcall | $0 | – | -100,000 | -100.0% | -0.14% | – |
| VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -205,000 | -100.0% | -0.14% | – |
| MEIP | Exit | MEI PHARMA INC | $0 | – | -410,000 | -100.0% | -0.16% | – |
| AKBA | Exit | AKEBIA THERAPEUTICS INC | $0 | – | -155,000 | -100.0% | -0.20% | – |
| AKUS | Exit | AKOUOS INC | $0 | – | -100,000 | -100.0% | -0.21% | – |
| SLNO | Exit | SOLENO THERAPEUTICS INC | $0 | – | -1,233,676 | -100.0% | -0.26% | – |
| CGEN | Exit | COMPUGEN LTDord | $0 | – | -200,000 | -100.0% | -0.28% | – |
| ENPH | Exit | ENPHASE ENERGY INC | $0 | – | -70,000 | -100.0% | -0.31% | – |
| CPRX | Exit | CATALYST PHARMACEUTICALS INC | $0 | – | -730,557 | -100.0% | -0.32% | – |
| ARYAU | Exit | ARYA SCIENCES ACQUISITION COunit 10/04/2023 | $0 | – | -200,000 | -100.0% | -0.38% | – |
| RTRX | Exit | RETROPHIN INC | $0 | – | -250,000 | -100.0% | -0.48% | – |
| XFOR | Exit | X4 PHARMACEUTICALS INC | $0 | – | -565,804 | -100.0% | -0.50% | – |
| DOV | Exit | DOVER CORP | $0 | – | -57,576 | -100.0% | -0.52% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INCcall | $0 | – | -228,700 | -100.0% | -0.55% | – |
| APRE | Exit | APREA THERAPEUTICS INC | $0 | – | -158,289 | -100.0% | -0.58% | – |
| PANW | Exit | PALO ALTO NETWORKS INC | $0 | – | -30,000 | -100.0% | -0.65% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -392,831 | -100.0% | -0.70% | – |
| WIX | Exit | WIX COM LTD | $0 | – | -37,588 | -100.0% | -0.91% | – |
| FIXX | Exit | HOMOLOGY MEDICINES INC | $0 | – | -658,919 | -100.0% | -0.94% | – |
| NVO | Exit | NOVO-NORDISK A Sadr | $0 | – | -400,000 | -100.0% | -2.46% | – |
| PFE | Exit | PFIZER INCput | $0 | – | -1,000,000 | -100.0% | -3.08% | – |
| BMY | Exit | BRISTOL-MYERS SQUIBB CO | $0 | – | -700,000 | -100.0% | -3.87% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -189,000 | -100.0% | -5.48% | – |
| XBI | Exit | SPDR SER TRput | $0 | – | -750,000 | -100.0% | -7.90% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.